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Abstract
Background: Long-term benzimidazole therapy benefits 
patients with non-resectable alveolar echinococcosis (AE). 
Methods to assess early therapeutic efficacy are lacking. 
Recently, AE liver lesions were reported to exhibit increased 
F-18-fluorodeoxyglucose (FDG) uptake in positron emission 
tomography (PET). To assess the value of FDG-PET for 
diagnosis and follow-up of AE patients. 
Patients/Methods: Twenty-six consecutive patients with 
newly diagnosed AE were enrolled. Baseline evaluation 
included CT and FDG-PET. Thirteen patients (11 women; 
median age 50 years, range 40-76) were resected, the 
remaining 13 (8 women; median age 60 years, range 
39–72) had non-resectable disease, were started on benzi-
midazoles, and CT and FDG-PET were repeated at 6, 12 and 
24 months of therapy. Twelve consecutive patients with 
newly diagnosed cystic echinococcosis (CE) of the liver 
were also subjected to baseline FDG-PET. 
Results: In 21/26 AE patients, baseline PET scans showed 
multifocally increased FDG uptake in the hepatic lesions’ 
periphery, while liver lesions were FDG negative in 11/12 
CE patients. Thus, sensitivity and specificity of FDG-PET 
for AE vs. CE were 81% and 92%, respectively. In 5 of 
10 non-resectable patients with increased baseline FDG 
uptake, the intensity of uptake decreased (or disap-
peared) during benzimidazole therapy, in 3 by ³2 grades 
within the initial 6 months.
Conclusions: FDG-PET is a sensitive and specific adjunct 
in the diagnosis of suspected AE and can help in differen-
tiating AE from CE. The rapid improvement of positive PET 
scans with benzimidazole therapy in some patients indicates 
that absent FDG uptake does not necessarily reflect parasite 
viability.
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Abbreviations
E. multilocularis   Echinococcus multilocularis
E. granulosus   Echinococcus granulosus
AE    alveolar echinococcosis
CE    cystic echinococcosis
PET    positron emission tomography
FDG    fluorodeoxyglucose
Introduction
The larval stage of the fox tapeworm Echinococcus mul-
tilocularis (E. multicocularis) causes in humans alveolar 
echinococcosis (AE), a disease primarily affecting the 
liver. E. multilocularis is prevalent throughout the northern 
hemisphere [1–3]. An annual incidence of AE of 0.2–1.4 
per 100,000 population has been estimated in central Eu-
rope [2, 4]. 
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Biologically, E. multicocularis behaves in the liver like a 
slowly, but invasively and destructively growing malignant 
tumor. Without treatment, >90% of patients die within 10 
years of diagnosis [1, 2, 5]. Radical resection is the treat-
ment of choice [3, 5, 6]. At diagnosis, however, only one 
third of AE lesions are still amenable to radical resec-
tion [4]. Long-term treatment with the benzimidazoles 
Mebendazole or Albendazole reduces 10-year mortality 
in non-resectable cases to less than 20% [2, 5]. While it is 
accepted that benzimidazoles are parasitostatic, i.e. inhibit-
ing disease progression, the controversy remains unsettled 
whether benzimidazoles may be parasitocidal, i.e. curative, 
and may therefore safely be stopped after years of treat-
ment in some patients. In a previously reported series of 
non-resectable AE, about one third of patients relapsed 
upon stopping long-term benzimidazole treatment, while 
the other two thirds did not [7, 8]. Moreover, parasite sam-
ples obtained from patients with long-lasting benzimid-
azole therapy proved still viable in an in vitro assay [5, 9]. 
Unfortunately, no clinical, laboratory or imaging marker 
has been identified for assessing the early therapeutic ef-
ficacy of benzimidazole therapy. This is largely due to the 
difficulty of predicting the parasite’s viability in vivo. 
In contrast to alveolar echinococcosis, treatment of cystic 
echinococcosis with an expanding growth and usually no in-
vasion and destruction by cysts, should be reserved for symp-
tomatic lesions or those affecting vital anatomical structures 
[3]. There have been no major clinical trials for any treat-
ment modality in patients with cystic echinococcosis.
E. multilocularis liver lesions were reported to show in-
creased FDG (fluorodeoxyglucose) uptake in PET imag-
ing, possibly reflecting parasite viability [10, 11]. The pur-
pose of this prospective study was therefore to determine 
the sensitivity and specificity of FDG-PET in the diagnosis 
of E. multilocularis liver lesions and to explore the evolu-
tion of FDG avid lesions during benzimidazole treatment. 
Patients and Methods
The study was performed according to the declaration of Helsinki. 
The protocol was approved by the hospital ethics committee and 
written informed consent was obtained from all participants. 
Patients with Alveolar Echinococcosis
From July 2000 to December 2004, patients (both genders, age 
18 to 80 years) with AE were eligible for the study, provided they 
fulfilled the following criteria: a) new diagnosis without previous 
treatment or benzimidazole therapy for less than 1 month or b) 
new diagnosis of recurrence after attempted radical surgery or c) 
progressive disease, despite benzimidazole therapy. 
Diagnosis of AE was based on morphological imaging studies 
(CT or MRI), serological results and/or histology, as defined by 
WHO [1]. Serum antibodies against Echinococcus antigens were 
determined by ELISA, as described [8]. 
At study entry, a contrast-enhanced CT was performed using 
a Siemens CT scanner (SomatomPlus 4, Siemens AG, Erlangen, 
Germany). Spiral CT sections of the neck, thorax, abdomen and 
pelvis were obtained according to the guidelines of the American 
College of Radiology. All E. multilocularis lesions were classified 
according to the PNM system describing the anatomical localisa-
tion and extent of AE, i.e. hepatic localisation/size of the para-
site (P), and absence/presence of involvement of neighbouring 
organs (N) and distant metastases (M) [6, 12]. In addition, the 
presence/absence of calcifications of E. multilocularis lesions was 
assessed.
A total of 32 patients with AE were referred to our Echino-
coccosis Clinic. Twenty six patients fulfilled the inclusion criteria, 
while 6 were excluded for the following reasons: referral after 
radical resection, only (n = 3); benzimidazole therapy for more 
than 1 month prior to referral (n = 1); age less than 18 years 
(n = 1) or more than 80 years (n = 1), respectively. 
Apart from echinococcosis, none of the AE patients 
presented evidence of active infection, except for one patient 
(Table 1, #14) who had HIV infection that was well controlled by 
antiretroviral therapy [13].
Patients with Cystic Echinococcosis
In order to define the specificity of FDG-PET for EM liver le-
sions, 12 consecutive patients with Echinococcus granulosus 
(E. granulosus), the dog tapeworm, causing cystic echinococcosis 
(CE), also underwent FDG-PET studies. They fulfilled the fol-
lowing criteria: a) newly diagnosed disease without previous treat-
ment (n = 6) or benzimidazole therapy for less than two weeks 
(n = 3), or b) recurrence after radical surgery treated with benz-
imidazole therapy for less than two weeks (n = 3). Diagnosis of 
CE was based on morphological imaging studies (CT or MRI) 
and serological results as defined by WHO [1]. In one of these 
patients serology and further work-up revealed later no evidence 
for CE and the diagnosis of a simple, benign liver cyst was made 
(Table 2, #12). 
None of the CE patients had evidence of active infections 
other than echinococcosis, except for one patient (Table 2, #11) 
who presented with symptomatic choledocholithiasis and mild 
cholangitis.
Follow-up Alveolar Echinococcosis
Thirteen of the 26 patients with AE underwent radical resection 
followed by a 2 years course of benzimidazole therapy [1, 6]. In 5 
of these 13 patients material from the E. multilocularis lesion was 
collected intraoperatively and subjected to viability testing using 
an animal model [9]. Twelve of the 13 resected patients survived 
and remain recurrence free, one (Table 1, #9) died from multior-
gan failure within the early postoperative period.
In 12 of the 13 non-resectable AE patients long-term benz-
imidazole therapy was started. One patient (Table 1, #20) with 
extensively calcified lesions and without detectable anti-Echi-
nococcus antibodies was followed without therapy. Four hours 
post-ingestion Albendazol and Mebdenazole serum levels were 
targeted to >1 umol/l and >250 nmo/l, respectively [5, 8]. 
Non-resectable AE patients were followed with physical exam, 
lab tests and imaging studies including CT and FDG-PET. One 
patient died 2 months after baseline examination from metastatic 
renal cell carcinoma (Tabel 1, #18). 
Viability Testing
In vivo viability testing was performed in jirds (Meriones un-
guiculatus), as described [9]. In brief, 0.25 ml homogenate 
prepared in physiological saline from an intraoperatively col-
lected portion of the E. multilocularis resection specimen was 
intraperitoneally injected in jirds (3–5 animals per specimen). 
After four to six months, animals were sacrificed and the ab-
domen macro- and microscopically examined for metacestode 
proliferation.
PET and PET/CT
A single baseline FDG-PET examination was performed in the 
patients with CE (n = 12) and in the patients with resectable AE 
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(n = 13). The non-resectable AE patients (n = 13) received a base-
line FDG-PET examination and those surviving (n = 12) were 
followed by FDG-PET at 6, 12 and 24 months, respectively, or 
until ³2 consecutive scans were negative. 
Initially FDG-PET and CT examinations were performed sep-
arately on the same day. Later-on, an integrated PET/CT device 
became available and PET examinations were performed using 
this new scanner.
PET-Imaging Protocol
FDG-PET-studies were performed on a GE Advance PET scan-
ner (GE Medical Systems, Waukesha, Wis., USA). The scanner 
acquires 35 2D sections of 4.25 mm thickness per increment with 
an axial field of view of 14.6 cm. The patients were explicitly asked 
to fast for at least 4 hours prior to the study. Fifty minutes prior 
to emission scanning, the patients received an intravenous injec-
tion of 300 to 400 MBq of FDG. Image reconstruction was per-
formed with a multiplicative iterative reconstruction algorithm 
for improvement of image quality and reduction of computation 
time [14].
PET/CT studies were performed on an integrated PET/CT de-
vice (Discovery LS, GE medical systems, Waukesha, Wisconsin, 
USA), combining the ability to acquire CT-images and PET data 
of the same patient in one session. A GE Advance NXi PET scan-
ner and a four-slice CT (LightSpeed plus) were integrated in this 
dedicated system. An unenhanced low dose CT was performed 
from the patient’s head to the pelvic floor. 
PET and PET/CT Image Evaluation
The PET scans were analysed by two board certified nuclear 
physicians with extended experience, first separately and then in 
consensus according to the procedure described below. They were 
blinded to clinical data, the results of laboratory and other imag-
ing studies, as well as to the final diagnosis. 
Images were visually analysed as follows. First, the readers 
analysed the attenuation-corrected PET images of every patient. 
Then, if available, the CT images, attenuation-corrected PET im-
ages, and co-registered PET/CT images were displayed together 
on the monitor, and the reviewers again evaluated the images. 
Physiological FDG uptake was identified, and excluded from fur-
ther analysis. 
In a second step, the lesions deemed to be pathological were 
classified according to a semi-quantitative FDG-uptake grading 
scale from 0 to 4: 0 = uptake as in the background, 1 = low uptake 
comparable to uptake in inactive muscles and fat, 2 = moderate 
uptake clearly noticeable and distinctly higher than uptake into 
inactive muscles and fat, 3 = strong uptake, but distinctly below 
FDG uptake noted in normal cerebral cortex, 4 = very strong 
uptake/comparable to normal cerebral cortex. This grading scale 
was adapted from Stumpe et al [15, 16]. It has been shown that 
classifying grade 3 and 4 lesions as infectious foci yields the best 
discrimination to non-infectious lesions. The presence or ab-
sence of the following was also recorded: Localization and size 
of the lesion, the extension/invasion into adjacent organs, the 
uptake pattern (diffuse, circular or focal) and whether there was 
metastatic spread into distant organs. 
AE was diagnosed in PET if pericystic FDG uptake was visible 
according to Reuter et al. According to our PET experience and 
the clinical features of AE and CE, the diagnosis of CE was made 
if no FDG uptake was present around the cyst. 
Statistics
Data are given as median and range. Mann-Whitney U or 
Fisher’s exact test were used for group comparison, as appro-
priate. A p value (two-sided) £0.05 was considered statistically 
significant.
Results
Baseline
Patients with Alveolar Echinococcosis (AE)
Twenty-three of the 26 patients had newly diagnosed 
disease (Table 1), whereas 3 had AE recurrence after at-
tempted radical resection and/or cessation of long-term 
benzimidazole therapy. Thirteen patients underwent radi-
cal resection, the remaining 13 presented with non-resect-
able lesions. There were no significant differences in age 
and gender distribution between resectable and non-re-
sectable cases. As expected, more patients in the resectable 
than in the non-resectable group had stage I-IIIa, i.e. less 
advanced, disease (p = 0.047).
Increased FDG uptake was observed in 21 of the 26 
patients, i.e. in 11 of 13 with resectable and in 10 of 13 
patients with non-resectable AE, respectively (p = n.s.). 
A typical example of increased perilesional FDG uptake 
in a patient with a large E. multilocularis mass in the right 
liver lobe (Table 1, #17) is depicted in Fig. 1. All positive 
cases showed focally increased FDG uptake in the lesion’s 
periphery. In eighteen of the 21 positive PET scans, the in-
tensity of FDG uptake was graded ³3, while it was graded 2 
in the remaining 3 patients. Five cases were PET negative, 
two of them (Table 1, #20 and #7) presenting with exten-
sively calcified lesions. Overall, sensitivity of FDG-PET for 
AE was 81% (21/26). 
Viability testing of E. multilocularis tissue removed at 
surgery was performed in 7 of the 13 resectable AE pa-
tients. Two of the 7 patients had PET negative lesions and 
viability testing was negative in both (Table 1, #7 and #11). 
However, only 1 of the 5 viability tests performed with ma-
terial of PET positive resection specimens yielded a posi-
tive result (Table 1, #12), the other four remained negative 
(Table 1, #1, #2, #13 and #9). 
Patients with Cystic Echinococcosis (CE)
Except for one patient, all CE cases were PET negative 
(Table 2). Thus, specificity of FDG-PET was 92% (11/12) 
in this series. Moreover, the sole positive CE patient (Table 
2, #11) was only weakly positive (grade 2) and presented 
with symptomatic choledocholithiasis. Thus, some cholan-
gitis-related weak PET positivity cannot be ruled out.
Follow-up of Non-resectable AE during 
Benzimidazole Therapy
All non-resectable AE patients were started on long-
term benzimidazole therapy, except for one patient 
without detectable anti-Echinococcus antibody levels 
(EmII/3–10 and Em2-plus-ELISA) and with an exten-
sively calcified, PET negative lesion that was deemed 
avital (Table 1, #20). He was followed without treat-
ment. One patient died from metastatic renal cell 
carcinoma before the scheduled follow-up PET 
(Table 1, #18). The median 4 h post ingestion serum level of 
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Table 1
Demographics and baseline characteristics of patients with resectable (# 1-13) and  non-resectable (# 14-26) alveolar echinococcosis.
# Gender 
(M/F)
Age at
diagnosis 
(years)
Clinical 
settinga
PNM
classificationb
PNM stagec 
(I–IV)
PETd
(pos./neg.)
PET gradee
(1–4)
1 M 50 New P1 N0 M0 I Pos. 3
2 F 65 New P1 N0 M0 I Pos. 4
3 F 40 New P1 N1 M0 IIIb Pos. 3
4 F 57 New P1 N0 M0 I Pos. 2
5 F 68 New P4 N1 M0 IV Pos. 4
6 F 56 New P1 N0 M0 I Pos, 3
7 F 68 New P1 N0 M0 I Neg. 0
8 M 49 New P2 N0 M0 II Pos. 3
9 F 47 Prog NAf NAf Pos. 3
10 F 76 New P2 N0 M0 II Pos. 3
11 F 50 New P1 N0 M0 I Neg. 0
12 F 46 New P3 N0 M0 IIIa Pos. 3
13 F 48 New P3 NX M0 IIIa/b Pos. 4
Summary 11/13 F 12/13 New 10/13 I–IIIag 11/13 Pos. 
Median 50
Range 40–76
14 M 39 New P3 N0 M0 IIIa Pos. 2
15 F 52 New P4 N0 M0 IV Pos. 4
16 M 60 New P4 N0 M0 IV Pos. 3
17 F 41 Rec P4 N0 M0 IV Pos. 4
18 F 69 New P1 N0 M0 I Neg. 0
19 F 52 Rec NAf NAf Pos. 2
20 M 70 New P1 N0 M0 I Neg. 0
21 F 72 New P1 N0 M0 I Pos. 3
22 F 62 New P4 N1 M0 IV Pos. 4
23 F 60 New P4 N1 M1 IV Neg. 0
24 M 64 New P3 N1 M1 IV Pos. 4
25 M 61 New P4 N1 M1 IV Pos. 3
26 F 55 New P4 N1 M1 IV Pos. 3
Summary 8/13 F 11/13 New 4/13 I–IIIag 10/13 Pos. 
Median 60
Range 39–72
a  New = newly diagnosed disease, Rec = newly diagnosed recurrence of disease after curative resection (#19) or 5 years after cessation of long-term 
benzimidazole therapy (# 17), Prog = progressive disease as evident from clinical signs/symptoms, imaging, and lab tests, despite adequate benz-
imidazole therapy; b  Classification of AE lesions according to localisation/extent of primary parasitic lesion (P), involvement of neighbouring organs 
(N) and distant metastases (M) [1, 5]; c  Staging of AE according to PNM classification, stage I-IIIa representing lesions more localised stages con-
fined to the liver, stages IIIb and IV more advanced stages including extrahepatic involvement [1, 5]; d  18-F-Fluorodeoxyglucose Positron Emission 
Tomography; e  Semiquantitative grading of intensity of 18-F-Fluorodeoxyglucose uptake in Positron Emission Tomography according to reference 15 
(0 = FDG-uptake as in the background, 1 = low FDG-uptake comparable to uptake in inactive muscles and fat, 2 = moderate FDG-uptake clearly notice-
able and distinctly higher than uptake into inactive muscles and fat, 3 = strong FDG-uptake, but distinctly below FDG-uptake noted in normal cerebral 
cortex, 4 = very strong FDG-uptake/comparable to normal cerebral cortex); f  Not available; g  Stage distribution I-IIIa and IIIb-IV in resectable vs. 
non-resectable group, p = 0.036 (Fisher’s exact test)
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albendazole was 4.2 umol/l (range 0.6–14.9), that of 
mebendazole 261 nmol/l (50–1689) respectively. 
In 5 of 10 non-resectable patients with positive FDG-
PET at baseline, PET positivity on follow-up scans had 
decreased in intensity grade (n = 1) or disappeared com-
pletely (n = 4) after 24 months of benzimidazole therapy. In 
3 of these 5 patients, FDG uptake decreased by ³2 grades 
within 6 months of starting benzimidazoles. On the other 
hand, PET positivity remained stable in 2/10 and increased 
in 3/10 patients, respectively. None of the two surviving 
baseline PET negative patients became PET positive dur-
ing follow-up.
Benzimidazole drug levels did not significantly differ 
in patients with and without improvement or loss of PET 
positivity, median 4h post ingestion levels of albendazole 
amounting to 3.6 umol/l (0.6–7.5) and 4.6 (1.9–14.9), those 
of mebendazole to 116 nmol/l (50–261) and 299 (140–1689), 
respectively (both p = ns). Comparison of the baseline 
characteristics of the 5 patients with improvement/loss of 
PET positivity to those of the 5 patients without revealed 
no significant differences in gender, age, PNM stage, spe-
cific anti-Echinococcus antibody levels, or local extension 
and/or intensity grade of baseline PET positivity (data not 
shown). 
Discussion
Recently, Reuter et al. reported that E. multilocularis liver 
lesions may show FDG uptake and thus be visualized with 
PET [10]. It was suggested that a positive FDG-PET scan 
may reflect parasite viability in vivo and thus may poten-
tially be useful in deciding on stopping long-term benzimid-
azole therapy in some non-resectable cases [11]. However, 
interpretation of these data is difficult since a limited num-
ber of patients with a rather heterogeneous disease history 
was studied, including newly diagnosed cases and patients 
treated for various times with benzimidazoles. 
Our study demonstrates a high diagnostic sensitivity and 
specificity of FDG-PET in differentiating CE from AE 
which may be difficult by conventional imaging modalities 
and serology alone. Thus, FDG-PET represents a valuable 
diagnostic adjunct in suspected hepatic echinococcosis. 
The lack of perilesionally increased FDG uptake in CE 
would be compatible with a smaller mass of glucose me-
tabolizing parasitic tissue or with a lower rate of glucose 
metabolism in CE compared to AE. Alternatively, a dif-
fering reaction of the host to the parasite may be involved. 
The morphology of the parasite-host relationship differs 
markedly between CE and AE [1, 17, 18]. CE lesions are 
characterized by a broad homogeneous capsule composed 
of laminated parasite and perilesional fibrotic host tissue, 
whereas E. multilocularis grows multifocally and invasively 
with protrusions of its germinal layer into the host tissue 
causing an intense inflammatory host reaction. 
Increased FDG uptake has been observed in tumoral 
and inflammatory/infectious lesions and a decrease in FDG 
uptake is considered a useful parameter in assessing the ef-
fect of anti-tumoral and anti-infectious pharmacotherapy 
[19]. The parasitic proliferation in AE occurs typically in 
Figure 1. Depicted is an example of coronal sections (Panel A) and transverse sections (Panel B) of a large cystic lesion in the right liver lobe 
(arrows) in a patient with alveolar echinococcosis (Table 1, #17), as assessed by computerized tomography (CT), fluorodeoxyglucose (FDG)-
positron emission tomography (PET), and combined PET/CT. Note the multifocally increased FDG uptake in the periphery of the lesion (arrows), 
while its centre exhibits irregular calcifactions on CT and does not take up FDG in PET, compatible with extensive necrosis.
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foci at the periphery of lesions where also increased FDG 
uptake is located. FDG uptake is absent in the centre of 
AE lesions where mostly necrotic material is found. 
Interestingly, the decrease in intensity or complete loss 
of FDG uptake observed during benzimidazole therapy 
in 5 out of 10 patients with non-resectable AE occurred 
rapidly, often within the first 6 months of treatment. This 
makes a decrease/loss of FDG uptake unlikely to reflect 
death of the parasite. Thus, in a previous study AE recur-
rence was observed after stopping long-term (average 4.3 
years) mebendazole therapy in 7 of 19 patients within 6–24 
months, proving that the parasite was still vital in 1/3 of 
patients after years of benzimidazole treatment [7]. 
At present it seems not possible to attribute the in-
creased FDG uptake in the periphery of AE lesions to 
parasitic metabolic activity and/or vitality, perilesional 
inflammation, or a combination of both.
The issue of FDG uptake and parasite vitality has to 
be discussed also in the context of the 5 AE patients with 
negative baseline PET studies. It is tempting to speculate 
that these patients may have 
had so called “died-out” AE le-
sions. Spontaneous inactivation 
of AE lesions has been docu-
mented [20, 21] and recently 
reviewed [1, 2]. The following 
supports that the AE lesions in 
4 of the 5 patients with nega-
tive baseline FDG-PET were, 
indeed, “died-out”: material 
from AE lesions of both re-
sected patients tested negative 
in the in vivo viability assay 
(Table 1, #7 and #11); more-
over, in 2 patients with non-re-
sectable AE lesions (Table 1, 
#20 and #23) follow-up exami-
nations were fully compatible 
with died out lesions, i.e. were 
extensively calcified and/or re-
mained stable and PET nega-
tive, in one of them (Table 1, 
#20) even in the absence of 
benzimidazole therapy. The 
third patient with a PET nega-
tive AE lesion at baseline died 
from metastatic renal cell car-
cinoma prior to the 6 months 
follow-up examination (Table 
1, #18). While the lack of FDG 
uptake at baseline may have 
truly reflected avitality of the 
parasite in at least 4 of the 5 
patients, alternative explana-
tions for PET negative lesions 
can not entirely be ruled out: 
a) the metabolic activity of the parasite may for 
some unexplained reason(s) have been spontane-
ously too low to be picked up by PET and/or b) PET 
positivity of very small peripheral foci may have been 
missed due to the limited spatial resolution of the PET 
scanner (5 mm). 
Material obtained at resection from only 1 of 5 PET 
positive patients tested positive in the in vivo viability as-
say (Table 1, #12). The sensitivity of this assay in untreated 
AE cases has been reported to be 80% [9]. EM is known 
to grow and proliferate in discrete foci at the lesions pe-
riphery, only. The low percentage of positive viability tests 
(20%) in the current series may be attributable to sampling 
error introduced by failing to systematically random sam-
ple the entire periphery of the resected specimen. Thus, 
the material subjected to viability testing may have been 
collected by chance from a portion of the resection speci-
men not containing viable parasite. 
Our study complements the reports by Reuter et al. 
[10, 11]. In follow-up of their earlier work [10], these 
Table 2 
Demographics and baseline characteristics of patients referred for cystic echinococcosis.
# Gender 
(M/F)
Age at diagnosis 
(years)
Final diagnosis PET a 
(pos./neg.)
PET Gradeb 
(1–4)
1 M 45 Cystic echinococcosis Neg. 0
2 F 48 Cystic echinococcosis Neg. 0
3 M 42 Cystic echinococcosis Neg. 0
4 M 25 Cystic echinococcosis Neg. 0
5 M 42 Cystic echinococcosis Neg. 0
6 M 22 Cystic echinococcosis Neg. 0
7 F 60 Cystic echinococcosis Neg. 0
8 M 42 Cystic echinococcosis Neg. 0
9 F 32 Cystic echinococcosis Neg. 0
10 F 40 Cystic echinococcosis Neg. 0
11 F 67 Cystic echinococcosis Pos. c 2
12 M 69 Simple Benign Liver 
Cystd
Neg. 0
Summary 5/12 F 11/12 Neg.
Median 42
Range 22–69
a  18-F-Fluorodeoxyglucose positron emission tomography; b  Semiquantitative grading of intensity 
of 18-F-fluorodeoxyglucose uptake in positron emission tomography according to refer; ence 15 
(0 = FDG-uptake as in the background, 1 = low FDG-uptake comparable to uptake in inactive 
muscles and fat, 2 = moderate FDG-uptake clearly noticeable and distinctly higher than uptake 
into inactive muscles and fat, 3 = strong FDG-uptake, but distinctly below FDG-uptake noted in 
normal cerebral cortex, 4 = very strong FDG-uptake/comparable to normal cerebral cortex); 
c  Patient presented with symptomatic choledocholithiasis; d  This patient was referred for evalua-
tion of a cystic liver lesion which in the outside hospital was thought to represent E. granulosus, 
on further investigation (imaging and serology) turned however out to be a simple benign liver 
cyst
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authors discontinued benzimidazole therapy in 15 pa-
tients who exhibited PET negative lesions after an aver-
age of 5 years of benzimidazole treatment [11]. After a 
further 18 months off therapy, 8 of the 15 patients showed 
progression of the disease defined as either newly devel-
oped PET positivity (n = 6) or clinical signs of progression 
(n = 2). This further underscores that PET negativity does 
not necessarily indicate avitality of the parasite.
In conclusion, our study suggests that FDG-PET/(CT) is 
a sensitive and specific adjunct to the diagnostic armamen-
tarium in suspected AE and can help in differentiating AE 
from CE. The rapid improvement of positive FDG-PET 
scans with benzimidazole therapy indicates that absent 
FDG uptake does not necessarily reflect parasite vitality. 
A better understanding of the factors linking parasite me-
tabolism and vitality and/or inflammatory host responses to 
PET positivity or negativity warrants further evaluation.
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